Skip to main content

Table 1 CVR Treatment Outcomes of HIV RNA <50 c/mL at Week 48 by Baseline CD4 Cell Count, n (%).

From: Efficacy and safety by baseline HIV-RNA and CD4 count in treatment-naive patients treated With atazanavir/r and lopinavir/r in the CASTLE study

 

ATV/r

   

LPV/r

   

As-Randomized

<50

50–<100

100–<200

≥200

<50

50–<100

100–<200

≥200

ITT

n = 58

n = 45

n = 106

n = 222

n = 48

n = 29

n = 134

n = 228

Responder

45 (78)

34 (76)

80 (75)

178 (80)

30 (63)

20 (69)

104 (78)

182 (80)

Virologic failure*

7 (12)

7 (16)

17 (16)

26 (12)

6 (13)

7 (24)

13 (10)

24 (11)

Discontinued

6 (10)

4 (9)

9 (8)

16 (7)

12 (25)

2 (7)

16 (12)

20 (9)

On-treatment, n/N (%)

45/52 (87)

34/40 (85)

80/95 (84)

178/202 (88)

30/35 (86)

20/25 (80)

104/114 (91)

182/201 (91)

  1. *Includes never suppressed and on study through week 48, discontinued due to insufficient viral load response through week 48, and rebound without resuppression.